Investors sentiment increased to 1.57 in 2019 Q2. Its up 0.29, from 1.28 in 2019Q1. It improved, as 24 investors sold Sangamo Therapeutics, Inc. shares while 32 reduced holdings. 26 funds opened positions while 62 raised stakes. 73.13 million shares or 14.12% more from 64.08 million shares in 2019Q1 were reported.
Hhr Asset Mgmt Limited accumulated 189,360 shares or 0.15% of the stock. California State Teachers Retirement Sys holds 176,863 shares or 0% of its portfolio. Us Fincl Bank De holds 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) or 5,176 shares. Voya Invest Mgmt Ltd Co holds 0% or 44,098 shares. Capital Advisers Ltd invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Benjamin F Edwards Co Incorporated has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Schroder Invest Management Group reported 115,841 shares stake. Ubs Asset Management Americas Incorporated owns 799,455 shares. Parametric Assoc Ltd Liability Corp reported 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Fmr stated it has 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Geode Mgmt Ltd Liability Corporation reported 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Comerica Bancshares invested in 15,904 shares or 0% of the stock. Cubist Systematic Strategies Ltd Liability Corporation reported 68,478 shares stake. Ameritas Inv Prns Inc stated it has 9,803 shares or 0% of all its holdings. Davenport Ltd Liability Company reported 0.05% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO).
The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock increased 6.97% or $0.75 during the last trading session, reaching $11.44. About 2.00 million shares traded or 75.52% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has declined 8.32% since December 3, 2018 and is downtrending. It has underperformed by 8.32% the S&P500.
The move comes after 8 months positive chart setup for the $1.33B company. It was reported on Dec, 3 by Barchart.com. We have $12.36 PT which if reached, will make NASDAQ:SGMO worth $106.08 million more.
Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.30 earnings per share, down 66.67 % or $0.12 from last year’s $-0.18 per share. After $-0.24 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.
More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Businesswire.com which released: “Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting – Business Wire” on November 06, 2019, also Finance.Yahoo.com with their article: “Does Sangamo Therapeutics, Inc.’s (NASDAQ:SGMO) CEO Salary Reflect Performance? – Yahoo Finance” published on August 17, 2019, Fool.com published: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – The Motley Fool” on November 26, 2019. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Seekingalpha.com and their article: “Gene therapy stocks in focus after Astellas/Audentes deal – Seeking Alpha” published on December 03, 2019 as well as Nasdaq.com‘s news article titled: “Newmont Goldcorp to Sell Red Lake Complex to Evolution Mining – Nasdaq” with publication date: November 26, 2019.
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.33 billion. The company??s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.